In a mouse model of OC, the loss of tissue transglutaminase (TG2, an enzyme highly expressed in cancer cells) reduced the tumor burden in mice and decreased levels of myeloid cells (such as MDSCs and TAMs) in the peritoneal TME, while promoting the accumulation of CD8+ T cells in ascites and enhancing the cytotoxic function of CD8+ T cells (56). This evidence concerns the gene TGM2 and neoplasm.